Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TRN-007
- Development stage
- Preclinical
- Lead developer
- Turn Biotechnologies
01
Overview
TRN-007 is an investigational RNA-based therapeutic being developed by Turn Biotechnologies, in collaboration with Stanford University, for the treatment of hair disorders. The drug utilizes RNA interference (RNAi) technology as its mechanism of action, aiming to modulate gene expression involved in hair growth and follicle health. It is part of Turn Biotechnologies' pipeline leveraging their proprietary ERA (Epigenetic Reprogramming of Aging) platform to address age-related conditions and tissue regeneration. As of the latest updates, TRN-007 remains in preclinical development for hair diseases[1][2][4].
- Other names
- TRN 007TRN007TRN-007
Beyond the preview
Go deeper on TRN-007.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TRN-007.